TriSalus Life Sciences Q2 2024 GAAP EPS $(0.21) Beats $(0.41) Estimate, Sales $7.36M Inline
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences (NASDAQ:TLSI) reported Q2 2024 GAAP EPS of $(0.21), beating the analyst estimate of $(0.41) by 48.78%. The company also reported quarterly sales of $7.36 million, meeting the analyst consensus estimate and marking a 59.67% increase from the same period last year.
August 15, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TriSalus Life Sciences reported better-than-expected Q2 2024 GAAP EPS of $(0.21), beating the analyst estimate of $(0.41) by 48.78%. The company also met sales expectations with $7.36 million, a 59.67% increase from the same period last year.
The better-than-expected EPS and significant year-over-year sales growth are positive indicators for TriSalus Life Sciences. Beating EPS estimates by a wide margin and meeting sales expectations should boost investor confidence and likely lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100